Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial

Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Japan. Prognosis is poor, and until recently sorafenib was the only treatment option available for patients with unresectable disease. Lenvatinib is the first therapy to demonstrate noninferiority...

Full description

Bibliographic Details
Main Authors: Azuma, M. (Author), Ikeda, S. (Author), Ishii, M. (Author), Izumi, N. (Author), Kaneko, S. (Author), Kobayashi, M. (Author), Kudo, M. (Author), Meier, G. (Author), Pan, J. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2021
Subjects:
aged
anemia
antineoplastic agent
Antineoplastic Agents
Article
aspartate aminotransferase
body weight loss
carbanilamide derivative
Carcinoma, Hepatocellular
controlled study
cost benefit analysis
cost control
cost effectiveness analysis
Cost-Benefit Analysis
cost-effectiveness
decreased appetite
drug safety
European Quality of Life 5 Dimensions questionnaire
female
hand foot syndrome
health care system
hepatic encephalopathy
hepatocellular carcinoma
human
Humans
hypertension
intention to treat analysis
Japan
Japanese (people)
lenvatinib
liver cell carcinoma
liver function
Liver Neoplasms
liver tumor
major clinical study
male
neutrophil count
Phenylurea Compounds
platelet count
population research
practice guideline
probability
proteinuria
quality adjusted life year
quinoline derivative
Quinolines
reimbursement
side effect
sorafenib
treatment outcome
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items